Inventiva (IVA) Free Cash Flow (2019 - 2025)
Inventiva (IVA) posted quarterly Free Cash Flow of $121.7 million for Q2 2025, up 335.0% year-over-year from $28.0 million in Q2 2024, and up 335.0% quarter-over-quarter from -$51.8 million in Q2 2024.
Inventiva (IVA) Free Cash Flow (2019 - 2025) Analysis & Trends
Inventiva's Free Cash Flow history runs 6 years deep, the most recent figure standing at $121.7 million for Q2 2025.
- In Q2 2025, Free Cash Flow rose 335.0% year-over-year to $121.7 million; the TTM figure through Dec 2025 stood at $69.9 million (up 235.0% YoY), while the FY2025 annual figure was -$122.1 million, down 32.98% from the prior year.
- Free Cash Flow for Q2 2025 stood at $121.7 million, up from -$51.8 million in the prior quarter.
- The five-year high for Free Cash Flow was $121.7 million in Q2 2025, with the low at -$51.8 million in Q2 2024.
- The 4-year median for Free Cash Flow is -$22.5 million (2021), against an average of -$4.2 million.
- The sharpest annual moves came in 2021 and 2025: Free Cash Flow sank 262.03% in 2021, then soared 335.0% in 2025.
- Inventiva's Free Cash Flow stood at -$22.5 million in 2021, then fell by 17.76% to -$26.4 million in 2022, then sank by 95.78% to -$51.8 million in 2024, then jumped by 335.0% to $121.7 million in 2025.
- Business Quant data shows IVA's Free Cash Flow at $121.7 million in Q2 2025, -$51.8 million in Q2 2024, and -$26.4 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Inventiva | 888.89 Mn | 888.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 121.69 Mn |
| Jun 30, 2025 | 121.69 Mn |
| Jun 30, 2024 | -51.78 Mn |
| Jun 30, 2024 | -51.78 Mn |
| Dec 31, 2022 | -26.45 Mn |
| Dec 31, 2022 | -26.45 Mn |
| Sep 22, 2022 | -27.05 Mn |
| Sep 22, 2022 | -27.05 Mn |
| Dec 31, 2021 | -22.46 Mn |
| Dec 31, 2021 | -22.46 Mn |
| Jun 30, 2021 | -14.32 Mn |
| Jun 30, 2021 | -14.32 Mn |
| Mar 31, 2021 | -9.34 Mn |
| Mar 31, 2021 | -9.34 Mn |
| Dec 31, 2020 | -8.55 Mn |
| Dec 31, 2020 | -8.55 Mn |
| Jun 30, 2020 | -3.96 Mn |
| Jun 30, 2020 | -3.96 Mn |
| Mar 31, 2020 | -3.95 Mn |
| Mar 31, 2020 | -3.95 Mn |